Posted in | News | Laser | NanoOptics

Proceeds to Advance Development of Novel Short-Wavelength Light Sources

Energetiq Technology, Inc., a developer and manufacturer of specialized short-wavelength light products for advanced technology applications, today announced that it has raised additional capital in its Series C round of financing. The financing was led by a new investor, Ushio Inc. , and supported by existing investors including Intel Capital and Shea Ventures.

Paul Blackborow, Energetiq's CEO stated, "We are extremely pleased to have the strong support of these investment partners as we grow our sales and advance our R&D efforts in short wavelength light source technology. This funding will enable us to aggressively pursue the development of our latest light source innovation, the Laser-Drive Light Source (LDLS(TM)), for which we were recently granted a US patent. We plan to adapt this new light source technology for use in life science analytical instrument applications and semiconductor manufacturing."

Tatsushi Igarashi, Executive Vice President for Technology at Ushio commented, "We at Ushio were impressed by Energetiq's ability to rapidly develop and commercialize valuable new technologies in the advanced light source area. We are pleased to participate in Energetiq's growth."

Since its beginnings in 2004, Energetiq has achieved significant success with customer adoption of its Extreme Ultraviolet (EUV) and Deep Ultraviolet (DUV) light source products in major research and manufacturing centers across the United States, Europe and Asia. Using patented technology, the Energetiq products have proven to be highly repeatable, reliable and cost-effective sources of short-wavelength light necessary in the production of the world's next generation nano-scale devices.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.